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ABSTRACT 
Dental implants are an effective method of restoring missing teeth without compromising 
healthy neighboring teeth. Under proper oral hygiene and adequate care dental implants may be 
maintained for over 10 years. 
Good bone and gingival health are necessary for successful implants. In general systemic 
diseases may lead to lower rates of dental implant success. In spite of the risk the use of implants 
is not contraindicated. 
The effectiveness of antiretroviral therapy has increased the span and quality of life in 
HIV positive patients. Currently, HIV positive patients can opt for advanced dental treatments 
such as dental implants to restore their smile and masticatory function. Implants require a 
surgical approach which has the same level of invasiveness and risk of infection as tooth 
extraction. It is still questionable whether implants are a viable alternative for HIV positive 
patients as HIV infection itself and antiretroviral therapy both lead to bone loss. There are 
insufficient longitudinal studies to determine the success of dental implants in HIV positive 
patients. 
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Recruited subjects for this study were scheduled for a single visit at GSDM to evaluate 
the current status of their implants previously placed at GSDM. Their medical history was 
updated including antiretroviral treatment. After a medical interview an intraoral radiographic 
image of the dental implant was used for comparison with the one taken at the date of implant 
placement to measure the amount of bone loss around the implant.  
This study aimed to determine if an unmodifiable factor such as HIV and the use of ART 
may affect the success of dental implants. Due to the small sample size, we may not conclude 
that HIV itself or the use of antiretroviral therapy affect the outcome of dental implant. The study 
supports the use of dental implants on HIV positive patients and the success of them is 
comparable to those placed on non-HIV patients. 
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INTRODUCTION 
1.1 HIV/AIDS epidemic in USA 
Human Immunodeficiency Virus (HIV) may have spread from primates to humans in the 1900s. 
HIV caught the world’s attention during the 1980’s when homosexual men began to present with 
advanced and unexplained immunodeficiency. The disease was later named AIDS and 2 years 
after in 1983 the 1st reported case the causative virus was identified as HIV. Intense research 
began to determine the pathogenesis and to develop protocols for treatment and prevention of 
HIV. While HIV infection was initially associated with homosexual men it later included drug 
users who shared needles then to hospital patients who received blood transfusions and was 
finally extended to the general population. HIV has infected more than 75 million people 
worldwide and an estimated 37 million individuals are currently living with the virus (Fact sheet, 
2015). In the US 1.1 million people are living with HIV and 1 of 7 are not aware that they have 
latent infections. (Fast Facts, 2013) 
In general HIV infections are declining in the United States while survival times are 
increasing. This may be due to targeted prevention efforts, improvement in the antiretroviral 
therapy and increased access to medication.  The estimated annual number of infections declined 
10% from 2010 (41,900) to 2014 (37,600) (Fast Facts, 2013). US Centers for Disease Control 
and Prevention reported a plateau in the pandemic infection. The incidence of newly infected 
individuals decreased from 3.1 million in 1991 to 2.2 million in 2001 and 1.8 million in 2009. 
HIV infections are highest in developing countries that have low socioeconomic populations and 
minimal or no understanding of prevention protocols and mechanisms of transmission of the 
disease. Regions such as sub-Saharan Africa, Central and South-East Asia, eastern Europe and 
South America have the highest rates. Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan and 
Turkmenistan have the fastest growing HIV epidemics. After the Soviet Union collapse there 
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was a rise in sex work and the use of injectable drugs, both risk factors for HIV transmission 
when having unprotected sex or sharing needles (CDC, 2012). 
In 2016 39,782 individuals were diagnosed with HIV in the United States. The annual 
number of HIV infections declined 5% between 2011 and 2015. Homosexual and bisexual men 
accounted for 67% of all HIV diagnoses. Young African American homosexual and bisexual 
men had the largest number of HIV diagnoses with 10,223 new cases reported. (Granich, 2017) 
At the end of 2015 1 million adults and adolescents were living with HIV. Of these 
162,500 or 15%, were undiagnosed. The younger population is most likely to be unaware of 
HIV. In 2014 6,721 deaths were attributed directly to effects of HIV. (Granich, 2017) 
 
1.2 Human Immunodeficiency Virus (HIV) 
HIV stands for human immunodeficiency virus. If the virus is not treated it can lead to AIDS or 
acquired immunodeficiency syndrome. HIV specifically targets immune cells through the CD4 
receptor found in T-lymphocytes, monocytes, macrophages and dendritic cells. The virus 
requires a co-receptor such as the chemokine receptors CCR5 and CXCR4 to gain entry. CCR5 
is highly expressed in memory T-lymphocytes but not on naive T-lymphocytes while CXCR4 is 
expressed on both. CCR5 is also present on macrophages and dendritic cells. The virus can also 
attach to the follicular dendritic network. The virus is retained in the network and concentrates 
within B-cell follicles of lymph nodes. HIV may cause tissue fibrosis through several 
mechanisms including up regulation of T regulatory cells and release of transforming growth 
factor beta (TNF-B).  
When a person is infected with HIV the virus initially rests in mucosal tissues and within 
days can be detected in CD4+ T-cells at the site of infection. From there it can spread to 
lymphoid organs. At day 10 the virus can be detected in blood. During the next few weeks it 
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spreads exponentially and peaks at day 30 when antibodies against HIV are detectable. At this 
point the patient is most infectious, the immune system achieves some degree of control and the 
viral replication has reached a stable level. At that point HIV infection leads to a progressive loss 
of CD4+ T-cells and other immunological abnormalities that are not fully understood. The 
patient develops an exaggerated immunodeficiency and may develop characteristic opportunistic 
infections or oncological complications which leads to AIDS. A patient with HIV may progress 
to death over a period of 10 years on average however many progress more rapidly and a rare 
subset may never progress or progress very slowly.  
HIV integrates into the DNA of the host genome. After entry the single strand of RNA is 
reverse transcribed into HIV DNA which integrates in the host DNA. This makes it exceedingly 
difficult to eradicate the virus. Using the energy and proteins of the host the HIV virus DNA is 
transcribed into the messenger RNA, proteins are produced and cleaved and newly formed virus 
particles are released. Entry inhibitors, reverse transcriptase inhibitors, integrate strand transfer 
inhibitors and protease inhibitors are commercially available therapies to inhibit viral replication.  
There are two main strains of HIV: HIV-1 and HIV-2. HIV-1 is the dominant and most 
pathogenic strain and is responsible for the vast majority of global infections. The difference 
between the strains is a result of cross-species transmission of simian immunodeficiency virus 
(SIV) from chimpanzees and sooty mangabeys. SIV in their natural host is less pathogenic than 
HIV-1. In humans-beings HIV-2 is less pathogenic than HIV-1 perhaps as the result of lower 
levels of replication. It is most prevalent in western Africa although small epidemics have been 
reported in Portugal, France, Spain and Brazil. HIV-2 incidence is declining due to the low 
replication rate and reduced viral load.  
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1.3 Antiretrovirals 
Antiretroviral therapy (ART) has improved the quality of life for an HIV infected individual. 
ART transformed HIV infection from a fatal disease to a manageable one. Initially clinicians had 
only limited success treating the opportunistic infections associated with the disease. Only after 
the HIV virus was identified and its life cycle understood were the medical and scientific 
communities able to develop antiretroviral medications. ART has been available for more than 
20 years and although not able to eradicate the disease it is highly effective. ART suppresses the 
rate of viral replication, improves the immune function, drastically reduces the risk of developing 
AIDS and slows the progression of the disease thereby increasing the life expectancy and 
improving the quality of life of people living with HIV/AIDS. (Oguntibeju, 2012) Prevention 
programs, research progress in development of new antiretrovirals and increased accessibility to 
ART have resulted in dramatic reductions in HIV/AIDS mortality and morbidity. Infected 
patients who stringently comply with medication protocols are healthier and can lead productive 
lives. Twenty-five anti-HIV agents are licensed and approved for use in adults by US and 
European regulatory agencies. Evidence-based guidelines have been developed for their optimal 
use. More than 4 million low and middle income individuals have access to antiretrovirals and 
their life expectancy is approaching that of uninfected individuals.  
HIV therapy first began in 1987 with azidothymidine (AZT, also known as Zivudine) 
which decreased the mortality and opportunistic infections in patients with AIDS. AZT was 
originally used as an anticancer treatment, it blocks reverse transcription of the HIV-1virus. Viral 
resistance quickly developed and new drugs were necessary to target viral replication. It took 
almost a decade for the introduction of combined therapy. This approach used different drugs to 
target points of viral replication and to limit viral resistance in more than one pathway. The 
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introduction of protease inhibitors along with to nucleoside reverse transcriptase inhibitors 
(NRTIs) in combination with (AZT) markedly reduced HIV mortality. 
ART combinations have proven efficacious in HIV prevention when used as post 
exposure prophylaxis and to prevent mother-to-child transmission. ART should begin as soon as 
possible after a subject is known to be infected. If the drug regimen is not followed closely the 
virus almost invariably rebounds within weeks. 
Multiple studies have shown the efficacy of ART, a clear example is the study published 
by Paella et al. in 1998 about the decline of mortality and morbidity among patients with 
advanced HIV. His team analyzed data from 1255 patients with CD4 counts below 100 cmm³ in 
nine clinics specializing in HIV infection from eight cities of United States between 1994-1997. 
Mortality declined up to 30% regardless of the gender, race, age and risk of HIV transmission. 
The incidence of opportunistic infections declined as well. The use of combination therapy ART 
seemed to have the most beneficial results and therefore the authors concluded that the declines 
of HIV mortality and morbidity could be attributed to the use of intensive ART. (Paella Jr et al. 
1998) 
 
1.3.1 Nucleoside reverse transcriptase inhibitors 
Nucleoside reverse transcriptase inhibitors (NRTIs) act by blocking reverse transcriptase. They 
terminate DNA synthesis by acting as analogues of natural nucleosides and nucleotides that are 
incorporated in DNA synthesis. Currently tenofovir and emtricitabone or abacavir and 
lamivudine are used as ‘backbone” regimens recommended for daily use. Tenofovir is associated 
with renal and bone disfunctions. Tenofovir alafenamide fumarate (TAF) demonstrates less 
toxicity and has greater penetration into lymphoid tissues than tenofovir and its expected to 
replace tenofovir  in most future regimens. 
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Abacavir is associated with life-threatening allergic reactions in individuals who have an 
HLA-B*5701 allele. Before prescribing abacavir testing for the allele is required. Abacavir may 
be associated with increased cardiovascular disease but that is still debatable. 
Zivoudine, also known as AZT, and stavudine, both nucleoside analogues, are no longer 
widely used. Several potential complications have been associated with the use of these drugs 
including anemia, neuropathy, hepatic steatosis, lactic acidosis and potentially disfiguring loss of 
body fat (lipoatrophy). Zivoudine was once considered a first-line regimen but is now in the past, 
however it is still used as a second-line regimen in Sub-Saharan Africa.  
Toxicity concerns have led research groups to construct nucleoside analogue sparing 
regimens Due to the efficacy of these drugs, specially in patients with high viral loads, they are 
still considered the ‘backbone’ of ART. 
 
1.3.2 Integrase strand transfer inhibitors 
Integrase strand transfer inhibitors prevent the integration of the HIV genome in to the host 
genome. These drugs are potent, well tolerated and safe. Dolutegravir is a once daily treatment. 
Its use in combination with other drugs is superior to other regimens. Raltegravir is another 
integrase strand transfer inhibitor which has comparable efficacy as dolutegravir but is given 
twice daily.  
 
1.3.3 Non-nucleoside reverse transcriptase inhibitors  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit reverse transcriptase by a 
different mechanism than nucleoside reverse transcriptase inhibitors. These drugs cause a 
conformation change of the enzyme by adhering to a pocket close to the activation site. NNTRIs 
are potent, safe and easy to produce. As part of an ART with three-drug-regimens these drugs 
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have proven to be effective. In the past Efarivenz was the most widely used in high income 
countries. It is usually well tolerated but has some toxicity involving the central nervous system. 
It may increase the risk of depression and suicide. Nowadays Efarivenz is used in combination 
with other antiretrovirals and not taken alone. Nevirapine is the NNRTI of choice in low income 
countries due to its low cost and availability as a generic drug. Nevirapine can cause severe 
hepatotoxicity and rash when used in patients with high CD4 T cell counts. Rilpirivirne seems to 
be the best-tolerated NNRTI but less effective when there are high levels of HIV virus in the 
blood.  
 
1.3.4 Protease Inhibitors 
Protease inhibitors block the formation of viral proteins. As the virion (DNA with no viral 
protein envelope) matures long chains of polypeptides are enzymatically cleaved into functional 
proteins by the HIV protease. When used with two nucleoside analogues protease inhibitors are 
highly effective. Protease inhibitors generally cause mild gastrointestinal symptoms and 
dyslipidemia. Some have been associated with cardiovascular disease although that has not been 
demonstrated in the most widely used protease inhibitors; darunavir and atazanavir. Due to high 
manufacturing costs protease inhibitors are only used as second or third line regimens in low 
income countries. Darunavir is the only first-line protease inhibitor recommended by the US 
Department of Health and Human Services treatment guidelines.  
 
1.3.5 Entrance inhibitors 
An entrance inhibitor prevents the entrance of HIV into the cell. This drug works effectively if 
the patient does not have virus variants. Enfurvirtide binds directly to HIV but its rarely used 
because it is expensive and must be injected daily. 
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1.4 Prevention of HIV 
At one time despite the limited scientific studies to prove their efficacy condom use together 
with education and behavioral changes were the only effective means of preventing HIV 
infection. In 1994 ART was shown to be effective in the prevention of mother-to-child 
transmission of HIV. In 2011ART was used to provide a undetectable viral load and to limit the 
infection between couples where one partner was infected and the other was not. This resulted in 
a 96% reduction in the transmission rate. Currently studies are on going using of ART and 
combination approach for prevention. 
Mother-to-child transmission may be prevented by the use of ART. In 2013 it was 
estimated that 240,000 children were newly infected which was 58% fewer than 2002. Since 
2009 900,000 new cases have been prevented in children. 
Despite substantial public health investment in nearly all regions of the world less than 
half of the infected population are receiving ART. This takes into account that more than half of 
the population with HIV infections have not been diagnosed. Among those who have been 
diagnosed failure to adhere to treatment programs, and lack of routine monitoring to detect 
treatment failure and worldwide accessibility limit the success of ART. 
 
1.5 Quality of life of people living with HIV and AIDS and antiretroviral therapy 
Quality of life is a concept that covers factors including physical, cognitive, emotional and social 
functioning. Factors that may affect the quality of life of those with HIV infection include: 
polypharmacy, treatment toxicity, poor mental health related to the burden of a lifelong chronic 
condition, substance abuse, social isolation and stigma. Compared to the general population the 
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quality of life of individuals with HIV is significantly lower. This is not taking into account other 
factors such as socioeconomic status and access to health care.  
The use of ART has become the cornerstone of the clinical intervention that is available 
to prevent transmission and slow progression of HIV infection in people living with HIV/AIDS. 
“Although ART has its limitations it saves lives and improves immune system function, reduces 
the risk of many HIV-related and “non-AIDS” complications and reduces the risk of HIV 
transmission.” (Oguntibeju, 2012). The mortality and morbidity benefits of ART are obvious. In 
asymptomatic patients with higher CD4 counts (>350 cells/mm³) it’s unclear when to start ART. 
However the risk for adverse outcomes increases as the CD4 count declines. In patients with 
counts <200 cells/μL ART dramatically decreases morbidity and mortality. Studies have shown 
that counts between 200-350 cells/mm³ demonstrate a reduction in both AIDS and non-AIDS 
events related to complications among who start ART with counts >350 cells/μL rather than 
<350 cells/μL. (Oguntibeju, 2012) 
Reports show that HIV/AIDS patients face various psychological problems, such as 
stigma, poverty, depression, substance abuse and cultural beliefs which can affect their quality of 
life not only from physical health but also from mental and social health which can cause 
problems that affect important activities. (Aranda-Naranjo, 2004) The development of ART has 
shifted the perception of HIV/AIDS from a fatal to a chronic and potentially manageable disease. 
Clinical improvement of HIV-infected patients under ART has often been measured by reduction 
in mortality, opportunistic infection rates, or severe AIDS-related symptoms. (Oguntibeju, 2012) 
ART has had an impact in the psychiatric symptoms of HIV-infected patients. Those receiving 
care and who continued the ART regime showed improvements in quality of life. Adherence is 
the critical component for the therapeutic success of control of HIV infection, although quality of 
life has been an important outcome. Adherence is the main determinant of biological measures of 
 10 
 
success in control of HIV including HIV RNA level, CD4 lymphocyte count and genotypic 
resistance. (Oguntibeju, 2012)  
 
1.6 Co-morbodities and negative effects of ART 
Traditional complications that lead to AIDS can be prevented today with the use of ART but 
some residual mobility risks persist such as osteoporosis, osteopenia, cardiovascular disease, 
some cancers, liver dysfunction, renal dysfunction and cognitive decline. Excess risk is seen 
when compared with age-matched individuals without HIV specifically concerning hypertension 
and hyperlipidemia. Many are due to traditional risk factors such as tobacco use and obesity. 
Much of the decreased quality of life appears to be due to persistent immune disfunction, 
inflammation and antiretroviral drug toxicity. 
Both clinical and experimental evidence exists for direct and indirect negative effects of 
ART. Some Protease Inhibitors (PI) may inhibit glucose intake into muscle and adipose tissue 
cells at the level of GLUT4. PIs may also affect hepatic very-low-density lipoprotein secretion 
through an inhibition of intracellular apoprotein B degradation. (Oguntibeju, 2012) An NRTI, 
fialuridine, although a very effective drug, may lead to a high incidence of subacute liver failure 
with symptomatic lactic acidosis. Lipodystrophy is associated with patients receiving ART. 
Recognition of lipodystrophy as a side effect of ART has led to reevaluation of the appropriate 
time to start ART, delay initiation of ART, and also to different modifications in ART for HIV 
treatment. Changes associated with lipodystrophy are mainly associated with an increased risk 
for developing symptomatic cardiovascular disease. (Oguntibeju, 2012) 
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1.7 HIV and ART both risk factors of bone loss 
Ofotokun and Weitzmann published a review of HIV-1 and ART as risk factors for osteoporosis 
and bone fracture. Metabolic complications including bone loss and fractures are becoming more 
common. Both HIV and ART may lead to bone loss although the exact mechanism is not 
understood. (Ofotokun and Weitzmann, 2010) 
Although low bone mineral density has been recognized in HIV/AIDS patients for more 
than a decade the large number of independent disease and lifestyle-related risk factors and 
complex HAART combinations used in clinical practice have generated confusion as to the 
causes and appropriate interventions. Brown et al. estimated that two of every three patients with 
HIV have osteopenia and an odds ratio of 3.7 of developing osteoporosis. (Brown et al. 2006) 
Paccou et al concluded that there is a 15% prevalence of osteoporosis and 52% prevalence of 
osteopenia in HIV patients. (Paccou et al. 2009) The question whether bone mineral density is 
related directly to HIV or as a consequence of traditional osteoporosis risk factors associated 
with the patient’s lifestyle (smoking and alcohol consumption) and diseases associated to AIDS 
such as muscle wasting, kidney disease, and hypogonadism is still in question. (Ofotokun and 
Weitzmann, 2010) 
ART does not prevent further bone loss and may exacerbate skeletal deterioration. ART 
may influence bone turnover independently of the bone loss associated with HIV-1 infection, 
although this may be relatively modest compared to the loss of BMD associated with other risk 
factors. ART has consistently been associated with up to 6% reduction in hip bone mineral 
density in the first years of taking ART. Some regimens of ART may be associated with more 
pronounced bone loss. Studies related to this topic have great variability due to the influence of 
important factors such as disease severity, prior ART, a wide range of ART regimens utilized, 
inadequate controlling of traditional osteoporosis risk factors, other disease-related effects, and 
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variability in anatomical sites chosen for BMD analysis. Brown et al. reported that loss of bone 
mineral density after ART initiation occurred independently of the antiretroviral regimen. 
Ritonavir, a PI, inhibits osteoclastogenesis and NRTIs may inhibit the activity of of bone 
forming osteoblasts. Whether or not ART leads to further reduction of bone mineral density is 
still debated. (Ofotokun and Weitzmann, 2010) 
 
1.8 Immunological prevention 
Prevention of HIV replication with use of ART prevents and often reverses HIV-mediated 
damage to the immune system. The majority of individuals who initiate, adhere and remain on 
suppressive therapy eventually achieve a normal or close to normal peripheral blood CD4 T cell 
count. Still there is a small minority of individuals referred to as immunological failures or non-
responses which means that although the virus is well-controlled their CD4 T cell count remains 
low (less than 350 per microliter). Persistent T-cell activation, hematopoietic stem cell failure, 
thymic dysfunction, residual low‐level HIV replication and other factors have been implicated in 
non‐response. Low CD4 T-cell count with therapy has been associated with increased 
cardiovascular disease, cancer and other co-morbodities. (Ofotokun and Weitzmann, 2010) 
 
1.9 Ryan White Foundation 
“The Ryan White HIV/AIDS Program provides a comprehensive system of care of the U.S. 
Department of Health and Human Services that includes primary medical care and essential 
support services for people living with HIV who are uninsured or underinsured. The Program 
works with cities, states, and local community-based organizations to provide HIV care and 
treatment services to more than half a million people each year. The Program reaches 
approximately 52% of all people diagnosed with HIV in the United States.” It gives access to 
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HIV medication. 2015 marked the 25th anniversary of Ryan White HIV/AIDS Program which 
was funded at $2.32 billion in fiscal year 2016. The Ryan White HIV/AIDS Program is divided 
into five parts. Part F provides grant funding that supports research, technical assistance, and 
access-to-care programs. These include educational and motivational programs, training and 
dental programs. The Dental Program provides additional funding for oral health care for people 
with HIV through the HIV/AIDS Dental Reimbursement Program and the Community-Based 
Dental Partnership Program. Grant recipients are dental education programs seeking to improve 
their response to the HIV epidemic in their area. Trustees of Boston University is one of the 11 
recipients of the FY 2017 Part F Community-Based Dental Partnership Program Grant Awards. 
In 2017 the total award was $3,189,991. Trustees of Boston University received $280,170. 
(Vazeux, et al. 1987) 
 
1.10 HIV and Oral Health 
HIV predisposes patients to certain oral health problems. “Antiretroviral therapies have reduced 
the overall prevalence of oral manifestations of HIV, but HIV-related oral conditions still occur 
in 30-80% of HIV-infected individuals. These orofacial conditions are readily detectable 
thorough examinations of the oral cavity.” Thirty to eighty percent of HIV-infected patients will 
present with HIV-related oral abnormalities. Xerostomia is common, occurring in up to 40% of 
HIV-positive patients. Most other oral conditions are caused by opportunistic infections 
including candidiasis (particularly angular cheilitis, erythematous candidiasis, and 
pseudomembranous candidiasis), bartonellosis, cryptococcosis, cryptosporidiosis, and 
histoplasmosis. Opportunistic viral infections may predispose patients to other conditions such as 
human papilloma virus may lead to condylomata, warts, or cancer; Epstein-Barr virus can lead to 
oral hairy leukoplakia; human herpesvirus may develop into Kaposi’s sarcoma; cytomegalovirus 
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may lead to cytomegalovirus oral ulcers. Herpes virus infection may also lead to necrotizing 
periodontal conditions that occur more frequently and progress more rapidly. Necrotizing 
ulcerative gingivitis or periodontitis occur in 2-6% of HIV-positive patients. Generalized chronic 
periodontitis is found in up to 30% of HIV-positive patients. The combination of periodontal 
disease, reduced salivary flow and antibodies increase the likelihood of caries. (Reznik, 2005) 
 
1.11 Dental Implants 
Dental implants are part of today’s modern dentistry but it took many decades before they 
acquired a favorable reputation. The turning point for dental implant acceptance was the design 
of the endosseous osseointegrated dental implant. They are the nearest equivalent replacement to 
natural teeth (Lamer, 1999). They became acceptable in 1977 in Sweden and internationally due 
to a conference held in Toronto in 1982. (Albrektsson, 2008) The acceptance resulted from long-
term successful clinical outcomes in edentulous patients. Early research was led by Branemark 
and his coworkers. Similar but independent research was done by Schroeder in Switzerland. 
Since then dental implants have become a popular, beneficial and successful treatment for many 
individuals.  
 
1.12 Dental Implants Success  
A fundamental issue concerning dental implants is the criteria used to determine success or 
failure. The criteria proposed by Albrektsson in 1986 is still considered the gold standard to 
define success of a dental implant. (Schwartz-Arad, 2005) Other criteria have been proposed to 
define success based on survival rate. 
The survival rate is the most important clinical criteria commonly reported. This simply 
means whether the dental implant is still physically in the mouth or has been removed. Critics 
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argue that implants that should be removed due to pain or disease may be maintained and 
wrongfully reported as successful. (Misch, 2008) Survival conditions of implants may have 2 
different categories: an implant with less than ideal condition but does not requires clinical 
management and compromised survival which includes implants with less than ideal condition 
that require clinical treatment to reduce the risk of failure. Implant failure is defined as implants 
that required removal. The term implant success is used to describe ideal clinical conditions. 
(Misch, 2008) 
Criteria Proposed By Albrektsson et al. 1986: 
1. Individual unattached implant that is immobile when tested clinically 
2. Radiography that does not demonstrate evidence of peri-implant radiolucency 
3. Bone loss that is less than 0.2 mm annually after the implant′s first year of service 
4. No persistent pain, discomfort or infection 
5. By these criteria a success rate of 85% at the end of a 5 year observation period and 
80% at the end of a 10 year period are minimum levels for success. 
 
1.13 Dental Implants in HIV  
The first factor taken into account when planning for dental implants is patient selection. (Donos, 
2014) Moy et al. concluded, in his prospective longitudinal study about risk factors for dental 
implants, that there is no absolute contraindication specifically for implant surgery and the 
decision of whether or not to place implants is left to the clinician’s knowledge of factors leading 
to higher risks of failure. The demand for dental implants has increased and so has the need for 
clear understanding of factors affecting selection of candidates. (Donos, 2014) (Moy, 2015) 
Absolute contraindications are like those for any other non-compulsory surgery and must 
be considered within a defined safety regimen. Absolute contraindications for implant surgery 
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and any other elective surgeries include: recent myocardial infarction (within the last 6 months), 
recent valvular prosthesis placement or transplant (last 6-12 months), high risk bleeding (INR 
greater than 3-3.5 and platelet count less than 50,000/mm3), significant immunosuppression 
(total white count less than 1,500-3,000 cells/mm3), active cancer therapy and/or intravenous 
biphosphonate treatment. Not only is the dental implant at a higher risk of failure but the 
patient’s health may be jeopardized and present a life-threatening event (Donos, 2014).  
Relative contraindications for dental implant surgery include: osteoporosis, patients 
taking antiresorptive medication or denosumab, rheumatoid arthritis, diabetes mellitus leading to 
impaired healing, cardiovascular diseases due to the risk of impaired blood supply, bleeding 
disorders leading to a high risk of hemorrhage, immunocompromised patients including AIDS. 
(Donos, 2014) (Moy, 2015) 
Uneventful wound healing is crucial for implant osseointegration and success. 
Immunocompromised patients may have a higher risk of implants failure. (Donos, 2014) “The 
available literature of implant success in HIV positive patients is limited, however dental 
implants have been associated with positive short-term outcomes in these patients”. (Donos, 
2014) 
Strietzel et al. presented a case report of three HIV positive patients taking HAART 
(highly active antiretroviral therapy). After implant placement and rehabilitation they concluded, 
“immunologically stable HIV-positive patients on HAART may be considered for implant-
prosthetic rehabilitation” (Strietzel, 2006). No modifications are required for dental implant 
procedures on HIV positive patients as long as their immune system status is stable.  
Oliveira et al. (2011) conducted a pilot study to compare the implant success rate in 40 
volunteers separated into three different groups: one composed of HIV-positive patients 
receiving protease inhibitor HAART; second composed of HIV-positive patients receiving 
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reverse transcriptase inhibitor-based HAART without a protease inhibitor and a control group of 
HIV-negative participants. Dental implants were placed in the posterior mandible and assessed at 
six and 12 months after loading. Success of the implants was analyzed in relation to CD4+ count, 
viral load and baseline pyridinoline and deoxypyridinoline values. No post-operative 
complications occurred and the dental implants in all groups successfully osseointegrated. 
Oliveira et al. concluded, “The use of endosseous dental implants in HIV- positive people was 
shown to be a good, reasonable, predictable and well-tolerated treatment option, despite CD4+ 
cell count, viral load levels or type of ART received,” even if the patient presented with bone 
mineral loss the implant success was not affected. (Oliviera, 2011) 
Regardless of the short-term efficacy of dental implants in HIV patients their long term 
predictability has not been reported (Donos, 2014) (Oliviera, 2011). Biphosphonate therapy is 
being considered as a potential treatment for HIV-positive patients with osteopenia which is 
another relative contraindication for elective surgery (Oliviera, 2011). The use of oral 
biphosphonate in HIV patients may be limited by gastro-intestinal side-effects and contribution 
to a high burden of ART and other medications. (Ofotokun and Weitzmann, 2010) The risk of 
bone loss or diminished bone mineral density due to HIV disease or the usage of ART as well as 
the treatment of osteopenia with biphosphonate may be considered risk factors to dental implant 
success. 
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METHODOLOGY 
2.1 Study design 
This study is an observational, retrospective and analytical study. 
 
2.1.1 Objectives 
To determine success of dental implants placed in HIV positive patients taking ART by 
measuring the amount of bone loss around their dental implants. 
 
2.1.2 Purpose 
The purpose of this study is to determine and analyze the bone loss around dental implants 
placed on HIV positive patients in GSDM in the last 15 years. 
 
2.2 Study population/sample size 
Sample size was determined by statistical calculation before data collection. To meet the 
criterion and to be able to obtain substantial results the sample size was determined to be 90. The 
goal of the study was to enroll 100 subjects in the research study. Initial screening of potential 
patients for the research was done by screening patient’s files in EDR (Electronic Dental 
Records) that included HIV+ in the medical history and the following implant related codes; 
implant placement, implant removal, implant-supported crowns or implant-supported dentures. 
The initial screening resulted in a total of 175 patients with more than 250 implants. The list 
needed to be filtered, specifically to implants placed at GSDM in the las 15 years. Any implant 
placed outside GSDM, removed or restored at GSDM but not surgically placed were excluded. 
The second screening reduced the list of potential patients to 70. Although not ideal it was still a 
good number to obtain results. All 70 potential patients were initially invited to participate in the 
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research by mail. If the patient wanted to participate he/she could contact the PI to schedule the 
appointment or if not interested he/she could respond to the opt-out letter later and send it to the 
school in the pre-stamped envelope. Patients who did not respond either way were contacted 1 
month letter via phone. Of the 70 patients 18 scheduled and participated in the research study. 
Three potential patients were removed from the 70 due to missing data that could have been 
obtained if the patient had participated in the research. The missing data included ART taken 
and/or  incomplete medical records. A total of 67 patients were included in the study and divided 
into 2 categories: charts and exam. Charts referred to the patient’s file revised before contacting 
them and exam referred to the patients who participated in the research appointment. All the 
parameters evaluated in the research were obtained from patient charts except the radiographic 
examination which could only be done if the patients actually came to GSDM for the research 
appointment. Total charts evaluated and included in the research were 67 of which 18 
participated in the radiographic analysis. 
 
2.2.1 Inclusion criteria 
Subjects included were required to meet the following criteria: 
1. Over 18 years of age when the implant placement was done. 
2. Health status: HIV positive patients, previously diagnosed before their initial dental 
visit, written in the dental records. 
3. Have dental implants placed in the last 15 years at GSDM 
4. Dental records of the dental implant placement, PA of the day the implant was placed 
5. English or Spanish speaking only (Spanish only because PI is fluent is both 
languages). 
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2.2.2 Exclusion criteria 
Subjects were excluded based on the following criteria: 
1. Pregnant women (women of reproductive age will receive a urine pregnancy test) 
2. HIV positive diagnosed after the dental implants were placed. 
3. Do not have any written records of dental implants placed at the BU dental clinic. 
4. PA x-ray of the dental implant of the day of implant placement. 
 
2.2.3 Screening methods 
The determination of number of patients necessary for this project was the first step to determine 
if this research  was viable. An initial request through the IRB used the digital filing program of 
GSDM, Salud® to match all patients who answered “yes” to the medical history question, “Do 
you have HIV?” and who have in their file any dental procedure code regarding dental implants. 
This includes dental implant placement, restorative procedures on dental implants (fixed and 
removal prothesis).  
The Ryan White Foundation is an inclusive foundation for funding dental and medical 
care of HIV positive patients. Although dental implants is not a procedure Ryan White funds 
screening files to determine which patients use the Ryan White Foundation is an additional and 
useful way to determine potential subjects for the research.  
One hundred and ninety eight subjects fulfilled the initial screening criteria of being HIV 
positive and having some dental implant procedure done.  
The list was then checked manually. Each patient’s dental file was read throughly to 
dismiss patients that did not fulfill the research criteria. All patients who had dental implants in 
their treatment plan but which were not actually placed were excluded. Dental implants placed 
by an external clinic but rehabilitated at the GSDM were also excluded. Implants with no record 
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of their size or brand or x-ray record of their placement were excluded. After a second filter for 
potential patients the list was narrowed to 70 patients who fulfilled the inclusion criteria. 
The 70 patients were contacted via mail. A letter to inform the subjects about the research 
was sent on behalf of Dr. Gail McCausland, Clinical Director and Clinical Associate Professor of 
the Periodontal Department. An additional letter was attached to the recruitment letter to give 
subjects the option to accept or decline the invitation. If the subject agreed to participate he/she 
contacted the PI or the Periodontal Department secretary using the number provided to schedule 
a single appointment for data collection, clinical screening and dental cleaning. If the subject did 
not desire to participate he/she can either call or check the decline check-box in the additional 
letter explaining that they do not wish to participate and did not wish to be further contacted. The 
additional letter could be returned to the school in the pre-paid envelope. See Appendix A, Initial 
Opt-Out Letter for Patient Recruitment. 
If the subject did not respond within a month he/she was contacted by phone by Dr. 
Nadine Cordero (P.I). This second attempt to contact the subject was done using a written phone 
script. The call mentioned the earlier  attempt to contact the subject, a description of the research 
and if they were interested in participating, an appointment could be scheduled. Their health 
status (being HIV positive) was never mentioned in the initial recruitment letter or phone call. 
This topic was not mentioned until the he/she accepted and arrived for the research appointment. 
See Appendix B, Phone Script for Patient Recruitment. 
If participants were potential child bearers a pregnancy test, provided by the PI, was 
required to proceed with the data collection. The main concern regarding this topic is the need 
for x-rays. Unnecessary radiation and all the risks included must be avoided.  
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Consent forms were provided in written form and explained verbally to the subjects. The 
subject was given time to read and ask questions regarding the research. Once he/she agreed and 
signed the data collection began. 
 
2.3 Measurement method/instrument  
Data collected by means of verbal communication of a written questionnaire and peri-apical x-
ray of the dental implant placed at GSDM. Measurements of bone loss around dental implants 
was done with ImageJ version 5.51. ImageJ is a public domain, Java-based image processing 
program developed at the National Institutes of Health. It can calculate area and pixel value 
statistics. Every image was measured and calibrated to obtain accurate results of bone loss 
related to the implant in the image. 
 
2.3.1 Patient Selection 
Initial data collection was obtained from 70 potential participants from their EDR in GSDM that 
fulfilled the inclusion criteria. 
A total of 18 of the 70 potential subjects agreed to participate in the study. Several 
reasons led to the small number of participating subjects. Those included if patients were; 
deceased, wrong phone number or address, living too far from GSDM and did not want to travel 
for a 1-hour appointment, patients moving away from Massachusetts and several patients 
unsatisfied with the dental treatment at GSDM and did not wish to return. Patients that 
participated were scheduled to be seen by the PI in the dental facilities of GSDM. These patients 
in general were easily contacted, frequent visitors at GSDM, in treatment or recently treated. 
Each subject was scheduled for a 2 hour appointment for clinical and radiographic data 
collection as well as a complementary dental cleaning and comprehensive dental examination. 
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Some of the participants did not wish to have a dental cleaning done because they had one 
recently or had one scheduled very soon.  
 
2.4 Questionnaires  
Questionnaires were divided into two parts. The first regarding the patient’s general health. The 
second form was used as a guideline for the clinical evaluation of the dental implant.  
Information regarding their medical status and medication were obtained through the 
subjects knowledge of their health. The questions regarding dental topics were mainly obtained 
from the subject’s EDR. See Appendices C and D.  
Patient Questionnaire included the following questions: 
1. Age 
2. Gender 
3. Date diagnosed with HIV? 
4. CD4 count (number of cells in cubic millimeter of blood) 
5. Are you taking ART (antiretroviral therapy)? 
6. Antiretroviral therapy taken 
7. Other medication 
8. In you lifetime, did you ever smoke more than 100 cigarettes? 
9. Do you currently smoke? 
10. Do you have diabetes? 
11. Have you had a myocardial infarction (heart attack)? 
12. Have you had a stroke? 
13. Have you ever been diagnosed with periodontitis (gum disease) before? 
14. In which department was/were the dental implant(s) placed? 
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15. Prosthetic therapy: Which department restored your dental implants? 
16. How often do you visit a dental clinic for maintenance and follow-up? 
17. How would you rate your overall health? 
18. How would you rate the health of your teeth and mouth? 
19. How many times a day do you brush? 
20. How many times a day do you floss? 
Basic information of age and gender was collected for each patient. HIV-related 
questions included date diagnosed with HIV (which only a few subjects and dental files included 
this information), CD4 count as a numerical evaluation of the severity of HIV; the usage of ART 
and if so which ART therapy the patient was prescribed. HIV-related topics were used in an 
attempt to relate their HIV status and treatment to the success of their dental implants. In the data 
parameters co-founding factors were also collected, those including the medication taken, 
smoking status, diabetes, history of stroke, and periodontal disease. 
Data collection related to the dental implant included, the department at which the 
implant was placed and rehabilitated for understanding of which departments within GSDM are 
treating HIV patients requiring dental implants. The following questions were based on the 
patient’s own evaluation: how often they visited the clinic for cleanings and follow-ups, their 
opinion about their overall health and oral health status. This data reflects their feeling toward 
their quality of life and was collected because ART treatment and dental implants are both aimed 
to improve patient’s quality of life. Data was also collected in regards to the number of times a 
day a patient brushes and flosses which is an indication of their care for personal hygiene 
specifically oral hygiene. 
Clinical examination was done using a periodontal probe, an explorer and and intra-oral 
mirror. The following were recorded: 
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1. Clinical findings (caries, presence of plaque, etc.) 
2. Periodontitis current status 
3. Antagonist to the dental implant 
4. Implant mobility 
Based on the patient’s EDR: 
1. Date of implant placement 
2. Implant placed in which tooth site 
3. Was bone augmentation necessary? 
4. What type of retention was used for the rehabilitation? 
5. Design of rehabilitation (fixed or removable) 
6. Dental implant commercial brand, diameter and length 
The EDR's were used for data collection. EDR’s were written by previous pre-doctoral 
students or post-doctoral residents who had previously treated the patients. The Principal 
Investigator based the data of the research study of the  EDR. Collecting information such as 
clinical findings, benefit the patient in the knowledge of their current dental status including 
caries, plaque. The current status of their periodontium was evaluated for periodontal disease by 
evaluating bleeding upon probing and deep pockets as well as history of periodontal disease 
treatment written in the EDR. 
Implant data included date of implant placement, tooth site, presence of bone graft at the 
site. Date of placement was used to refer to the x-ray taken at the time of placement. The implant 
tooth site is important to consider due to variability in bone quality and occlusal forces which 
vary between anterior and posterior sites. Previous bone augmentation was another factor that 
may affect the success of the implant due to the quality of bone itself. The type of implant 
retention was recorded, cemented or screwed retained. If the implant was restored with fixed or 
 26 
 
removable, single or multiple implants connected and occlusal antagonist (whether the implant 
rehabilitation occludes against natural tooth, porcelain or acrylic) was also reported as 
cofounding factors or variables that may affect the final results.  
Implant mobility and bone loss in x-rays was the primary data used to evaluate the 
success of the dental implants. Both parameters are found in Albrektsson’s Criteria to evaluate 
dental implant success. If an implant has mobility it translates to lack of osseointegration 
automatically considered a failing implant that requires removal. The bone level around a dental 
implant is related to the amount of bone loss and the time since the implant was placed. An 
implant with more the 50% bone loss is considered a failing implant.  
 
2.5 Radiographic examination 
A PA and a bitewing x-ray of the implant was taken using a positioning device and GSDM 
digital x-ray equipment of the Periodontal Department Dental Clinic. All radiographs were saved 
in the patient’s dental file in Mi-Pacs software. The amount of bone loss measured on the PA 
was determined by calibrating the radiographic image with ImageJ 5.51s. For each implant the 
diameter and length collected was used to calibrate the ruler to determine bone loss from the 
implant-abutment interface to the crestal bone in mesial and distal of the implant. See 
Appendices F and G. 
 
2.6 Clinical examination 
The clinical examination included a general dental check-up. Findings such as dental caries, deep 
periodontal pockets, tooth mobility and/or defective restorations were reported to the subject. If 
the patient required dental treatment and wished to be treated at GSDM they was referred to the 
responsible department for the necessary treatment.  
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The appointment concluded with dental prophylaxis using scalers, prophylaxis paste and 
a silicone cup.  
 
2.7 Data analysis 
Data from the survey was analyzed using SAS® (Statistical Analyses Software, Version 9.3, 
Cary, NC). The sample population is described with respect to demographics, clinical parameters 
and dental implant data. A total of 67 subjects were included in the study, data from 49 subjects 
were collected from their EDR only and 18 subjects data was based on the clinical examination 
and EDR. Exam records were compared to Chart records to show no significant difference 
between them. P-value more than 0.05 indicates no difference in the results between the Chart 
group and the Exam group. 
 
2.8 Ethics 
A letter of approval was obtained from the Institutional Review Board associated with the 
Boston Medical Center (BMC) before the study was undertaken (Approval letter). Informed 
consent was also obtained from all subjects during the study (Attach consent form). Data was 
recorded anonymously and strict confidentiality was maintained at all stages of the study.  
 
2.9 Limitations of the study 
The main limitation in this study was the quantity of subjects. Although 70 patients received 
letters and phone calls only a limited amount of subjects participated. Only 18 who participated 
for radiographic data collection and clinical screening. 
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Answers to the questionnaire were limited to the patient’s own knowledge and self-
criteria of their health. Medical consultation with their primary physician was not done to verify 
the medication taken by the subject or any changes in their medical history.  
The questionnaire was in English and well as in Spanish. It was not translated into other 
languages since none of the participants required translation to another language. 
The research data collection was limited to a single appointment unless the subject did 
not wish to stay for 2 hours. None of the participants rescheduled for cleaning and many actually 
declined the dental cleaning for several reasons such as already scheduled cleaning or recent 
appointments for the same reason. The group of patients who participated in the study were 
highly compliant in their maintenance appointments including hygiene cleanings and follow-ups 
after treatment.  
Another important limitation is the absence of standardized x-rays. Periapical x-ray taken 
at the time of implant placement was not indexed for comparisons of future x-rays. 
Discrepancies between the initial periapical x-ray and the current were expected with regard to 
the angulation and positioning. Although an XCP Extension one Paralleling Instrument (RINN) 
was used a personalized XZC to the patient’s bite would have increased the precision in the 
positioning of the current x-ray taken at the data collection appointment. Distortion was taken 
into account at the time of data analysis. This may have increased variation of the final results. 
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RESULTS 
3.1 Results 
Results of the data collected is presented in the following tables. 
 
  
Chart Exam Total P= 
Total number of subjects 
 
49 18 67 
 
Average Age 
 
58.2 (8.5) 59.1 (7.8) 58.4 (8.3) 0.6941 
Gender 
Male 83.7% 88.9% 85.1% 
0.7174 
Female 16.3% 11.1% 14.9% 
Table 1. Demographics 
Shows the number of participants, subdivided by charts screened before data collection and 
subjects who scheduled and participated in the exam and the total. Comparisons between the 
chart group and the exam group was done to determine if the results from the exam group would 
reflect the chart group. The groups were further divided by age and gender. 
 
General health 
E, VG 44.4% 
Good 44.4% 
F/P 11.1% 
Oral health 
E, VG 44.4% 
Good 44.4% 
F/P 11.1% 
Table 2. Self-rated Health Status 
The subjects who participated in the exam rated their general health and oral health as excellent 
(E), very good (VG), good (G), fair (F) and poor (P). These categories were clustered because 
the number of participants was only 18. Data was not collected from the chart group. 
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Brushing frequency 
>1/day 76.5% 
1/day 23.5% 
Flossing frequency 
1+/day 82.4% 
<1/d -never 17.6% 
Table 3. Brushing and Flossing Frequency 
Brushing and flossing frequency in the exam group. Brushing frequency more than once a day 
(>1/day) and 1 or less times a day (1/day). Flossing frequency more than once a day (1+/day) 
and (less than once a day or never (<1/d -never). Data was not collected from the chart group. 
 
 Category Total Chart  Exam P= 
History of periodontal disease yes 46.2% 53.2% 27.8% 0.0659 
Smoking status 
current 19.7% 22.9% 11.1% 
0.0011 former 19.7% 8.3% 50.0% 
never 60.6% 68.7% 38.9% 
History of diabetes yes 9.1% 4.2% 22.2% 0.0427 
History of myocardial infarction yes 4.6% 4.2% 5.9% 1.0000 
History of stroke yes 3.0% 2.1% 5.6% 0.4741 
Table 4. Medical History 
Subjects were asked about their history of periodontal disease, smoking status (current smoker, 
history of smoking more than 100 cigarettes, and never smoked), myocardial infarction, and 
stroke. 
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Medication Category Total Chart  Exam  
NONE N=5 n=4 n=1 
NRTI N=5 n=4 n=1 
PI N=0 N=0 N=0 
ISTI N=0 N=0 N=0 
NNRTI N=0 N=0 N=0 
NRTI+PI n=17 n=15 n=2 
NRTI+ISTI n=20 n=12 n=8 
NRTI+NNRTI n=23 n=20 n=3 
NRTI+ISTI+NNRTI n=1 n=1  n=0 
NRTI+PI+ISTI n=6 n=4 n=2 
NRTI+PI+ISTI+NNRTI n=3 n=3 n=0 
Table 5. Antiretroviral Medication 
HIV medication was taken by 100% of the subjects. Non-HIV related drugs were not included in 
the data analysis due to the small number of subjects, HIV related medication was divided into 
classes. Combination drugs were also included in the study. The classes include: Integrase 
inhibitors (ISTI) , Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), Non-
nucleoside reverse transcriptase inhibitors (NNRTIs), Protease inhibitors and others which 
include: Entry inhibitors and Chemokine co-receptor antagonists (CCR5 antagonists). None of 
the subjects examined took HIV medication from the category of “other” therefore it was not 
included in the table. Table 16 presents the number of subjects taking either a single class of HIV 
medication or a combination. 
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Medication Category Total Chart  Exam  P= 
ISTI 37.5% 31.8% 58.8% 0.0407 
NRTI 93.8% 93.6% 94.1% 0.9437 
NNRTI 33.8% 38.1% 17.6% 0.1136 
PI 32.5% 34.9% 23.5% 0.3735 
Table 6. Subcategories of ART 
HIV medication classes in percentages. Combination of medication was separated to the be 
included in each class. 
 
 
Category Total Chart  Exam P= 
Surgical Implant 
placement Department 
Perio 87.7% 87.2% 88.9% 
1.0000 
Other 12.3 12.8% 11.1% 
Restorative Implant 
Department 
Prosth 63.1% 68.1% 50.0% 
0.1389 
AEGD 15.4% 17.0% 11.1% 
Pre-doc 20.0% 14.9% 33.3% 
External/other 1.5% 0.0% 5.6% 
Table 7. School Departments for Implant Therapy 
Implants can be placed and restored in different departments at GSDM. Surgical implant 
placement is in the Periodontal Department (Perio) or Pre-doctoral department or the Oral 
Surgery Department, grouped as Other. Implant restoration is done by the Prosthodontic 
Department (Prosth), Advanced Education in General Dentistry (AEGD), Pre-doctoral 
Department (Pre-doc) or by an external referral (External/other). 
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Number of implants per subject Number of subjects Percentage 
1 25 37.3% 
2 25 37.3% 
3 6 9.0% 
4 7 10.4% 
5 3 4.5% 
6 1 1.5% 
Table 8. Number of Implants per Subject 
The amount of implants placed per subject (n) not specifically on the same date. 37.3% (n=25) of 
the subjects had 1 implant, 37.3% (n=25) had 2 implants placed. 9% (n=6) had 3 implants, 
10.4% (n=7) had 4 implants, 4.5% (n=3) had 5 implants and 1.5% (n=1) had 6 implants. 
 
3.1.1 Clinical Findings 
Clinical findings in our data included the information obtained from the chart reviews done 
before subject recruitment (chart) and subjects that physically attended the research appointment 
for the examination (exam). Total number of charts reviewed, n= 85 and the total number of 
examinations done n=18. 
 
 
Total subjects (%) Charts (%) Exam (%) P= 
Edentulous 19.5% 20.6% 16.1% 
0.5831 
Partially edentulous 80.5% 79.4 83.9 
Table 9. Edentulous and Partially Edentulous Percentages 
Number and percentage of subjects who are partially of fully edentulous. 
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Exam (%)  
Healthy 60.0% 
Periodontal disease 33.3% 
Edentulous 6.7% 
Table 10. History of Periodontal Disease 
Percentage of subjects previously diagnosed with periodontal disease as seen in the dental 
records, subjects not diagnosed with periodontal disease (healthy) and completely edentulous 
patients. History of periodontal disease was defined as having periodontal disease, previously 
treated with scaling and root planing, osseous surgery or diagnosed with “current status more 
than 2 teeth with BOP, suppuration, attachment loss greater than 2mm and/or periodontal 
pocket depth greater than 6mm”  at the clinical examination. 
 
 
Total Subjects (%)  Charts (%)  Exam (%)  P= 
No 12.8% 10.8% 19.0% 
0.4512 
Yes 87.2% 89.2% 81.0% 
Table 11. Percentage of Implants with Bone Augmentation 
Percentage of subjects who required bone augmentation (bone graft) before or during implant 
placement. Evaluation was done by revising dental history in subject’s chart. 
 
 
Total Subjects (%)  Charts (%)  Exam (%)  P= 
Screw retained 46.4% 49.4% 36.0% 
0.057 Cemented 45.4% 40.0% 64.0% 
Removable 8.2% 10.6% 0.0% 
Table 12. Type of Prosthetic Retention 
Implant prosthetic retention in percentages per implant.  
Prosthetic retention may be screw retained, cemented or categorized as removable if the patient 
wears a removable over-denture. 
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Total Subjects (%)  Charts (%)  Exam (%)  P= 
Single-unit 75.4% 72.2% 86.7% 
0.1043 
Multi-unit 24.6% 27.8% 13.3% 
Table 13. Type of Implant Prosthetic Design 
Prosthetic rehabilitation design per implant in percentages.  
Single unit is a single implant supported crown. Multi-unit refers to either a implant supported 
removable or fixed partial denture. 
 
 
Total Subjects (%)  Charts (%)  Exam (%)  P= 
Natural teeth 68.8% 71.0% 61.3% 
0.5863 Fixed prosthesis 21.0% 19.6% 25.8% 
Removable prosthesis 10.1% 9.4% 12.9% 
Table 14. Implant Antagonist Occlusion 
Antagonist occlusion of the implant in percentages per implant. Natural teeth for the implant 
occluding against teeth, fixed prosthesis includes implants occluding against fixed implant or 
tooth supported crowns or partial fixed dentures. Removable prosthesis are includes partial or 
full removable dentures tissue or implant supported. 
 
 
Total Subjects (%)  Charts (%)  Exam (%)  P= 
3i Biomet 12.4% 16.3% 0.0% 
0.0435 
Nobel 32.6% 30.6% 38.7% 
Straumann 42.6% 38.8% 54.8% 
Zimmer 12.4% 14.3% 6.4% 
Table 15. Implant Brand 
Brand of implants placed reviewed in the study. This includes 3i Biomet, Nobel Biocare, 
Straumann and Zimmer Implants. 
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Diameter (mm) Total Subjects (%)  Charts (%)  Exam (%)  P= 
3.0 0.8% 0.78% 0.00% 
0.3179 
3.3 17.05% 13.18% 3.88% 
3.5 14.0% 9.30% 4.65% 
3.7 3.1% 1.55% 1.55% 
4.0 4.7% 4.65% 0.00% 
4.1 17.8% 15.50% 2.33% 
4.3 13.2% 10.08% 3.10% 
4.5 2.3% 2.33% 0.00% 
4.7 78.0% 78.00% 0.00% 
4.8 15.5% 8.53% 6.98% 
5.0 10.1% 8.53% 1.55% 
6.0 78.0% 78.00% 0.00% 
Table 16. Implant Diameter 
Implant diameters evaluated in the study. Diameters range from 3.0-6.0mm. 
 
Length (mm) Total Subjects (%)  Charts (%)  Exam (%)  P= 
6.0 1.6% 1.55% 0.00% 
0.6526 
8.0 13.18% 10.08% 3.10% 
8.5 0.8% 78.00% 0.00% 
10.0 65.1% 46.51% 18.60% 
11.5 10.9% 9.30% 1.55% 
12.0 3.1% 2.33% 78.00% 
13.0 5.4% 5.43% 0.00% 
Table 17. Implant Length 
Implant length evaluated in the study. Lengths range from 6.0-13.0mm. Implants brands were 
recorded separately from the diameter and length.  
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Exam PA (mm) P= 
Mesial bone loss (mm) 0.669 
 
Distal bone loss - mm 0.351 
 
General bone loss (mean %) 5.2% (12.4%) range -16.6%-53.1% 
Table 18. Bone Loss Measured in Periapical Radiograph 
Radiographic measurements of bone loss measured in 27 peri-apical X-rays (PA) of dental 
implants. Measurements was reported in millimeters (mm) using the width and height of the 
implant as reference and adjusted for distortion due to angulation of the radiographic cone. Once 
the scale was adjusted bone loss was measured on the initial x-ray taken on the day of implant 
placement and on the examination day. Examination day was between 6 months up to 60 months 
after implant placement. Percentage of bone loss was analyzed to define the success rate based 
on Albrektsson’s criteria. Only subjects who came to the research appointment were measured 
for implant bone loss. On day the of the appointment a PA was taken of the implant or implants. 
 
Clinical Group N 
Minimum 
(months) 
Maximum 
(months) 
Mean 
(months) P= 
Chart 122 1 130 45 
0.08 Exam 19 7 139 32 
Total 141 
  
43 
Table 19. Time in Months Since Implant Placement to Last Follow-up Appointment 
Time since the implant had been placed. The duration of implant was obtained by subtracting the 
date charts were reviewed (2017) or subjects were examined in the clinic to the date of implant 
placement. Time was presented in months. Of 141 implants evaluated, the range was 1-139 
months. The average time since the implant was placed to the examination or chart review was 
43 months (3.6 years).  
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DISCUSSION AND CONCLUSION 
The goal of this study was to determine the success of dental implants in HIV positive patients 
taking antiretroviral medication. The success was determined by measuring crestal bone loss 
around dental implants. Clinical and radiographic examinations were done to determine the 
health and status of the implants in participating subjects. Due to the small number of 
participating subjects that were available for clinical data collection n=18, now (identified as 
Exam group) the protocol was amended to  review dental files retrospectively and data of 67 
subjects (identified as the Chart group) was analyzed and compared to data from the subjects 
who were examined at the research appointment. Chart group included subjects who were not 
able to participate but their dental charts had sufficient data to complete the questionnaire. This 
group was included in all data collection except follow-up intra-oral radiographic examination. 
An updated medication list was not able to be obtained from the from the Chart group so the 
reported medications from their dental charts was used. Altogether the total number of implants 
analyzed was 142. 27 implants had radiographic analysis completed from the Exam group. Three 
subjects scheduled an appointment for data collection but due to missing data in their charts their 
information was not included. Two subjects had panoramic radiographs as initial radiographs 
which could not be included. One subject who was not included in the radiographic examination 
was removed from the study because the dental implant PA and placement was not retrievable. 
 
4.1 Demographics 
The average age (Table 1) of the subjects included in the study was 58 with no difference 
between the Chart group and the Exam group. This is a common age for implant placement in 
the general population. Moy el al. (2005) published a retrospective study about risk factors and 
dental implant failure rates in which the median age was 58. Eighty-five percent of the subjects 
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in the study were male and 15% females. In 2016 hiv.gov reported that of individuals who are 
HIV positive gay and bisexual men remain most affected (up to 70%) with heterosexuals(23%), 
gay and bisexual men who inject drugs  (3%) and people who inject drugs (5%) making the 
remainder. The majority of participants in this study being male reflects the general population.  
Table 2 reflects the personal opinion of the Exam subjects about their health. success. 
This information was collected to see if the overall health and oral health status was correlated 
with implant. They were asked to specify how they felt about their overall health and their oral 
health separately and were given the choice of excellent, very good, good, fair or poor. The 
percentages for overall health and oral health were the same. Eleven percent of the subjects 
reported a fair or poor overall and oral health. The majority of the subjects believed their overall 
health and oral health was excellent or very good (44%) or good (44%). This belief reflect on 
their meticulous attention to periodontal maintenance visits and knowledge of their health such 
as viral load, CD4 count and medication taken for HIV and other diseases. When subjects were 
asked the frequency of brushing and flossing, 77% responded that they brushed more than once a 
day and 82.4% reported they flossed more than once a day (Table 3).  
Table 4 tabulates subjects that had common diseases or habits that may affect the success 
of dental implants. These include history of periodontal disease, history or currently smoking, 
diabetes, and history of myocardial infarction or stroke. In this study 46.2% had a history of 
periodontal disease treated at GSDM.  
The influence of general health problems on the implant failure rates is still poorly 
documented with only few controlled studies available (Chrcanovic, 2014). Moy et al. (2005), 
correlated diabetes, and other systemic diseases to the risk of implant failure. The results show 
that diabetes has a high relative risk (RR), RR=2.75 of implant failure as did smoking, RR=1.56. 
Twenty percent of the subjects included in this study were former smokers and 20% were current 
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smokers. Sixty percent of the subjects had never smoked. Twenty-two percent of the patients 
were diabetic. Moy mentions in his study that diabetic patients tend to have higher failure rates 
within the first year of implant placement rather than in the later years of implant use. Since this 
sample is small we cannot conclude that implant failure was related to the subject’s diabetes. 
Cardiac disease and hypertension had lower risks than diabetes and smoking, RR=1.02 and 
RR=0.95 respectively. Many patients who seek dental implants at age 50 or over may have either 
coronary artery disease or hypertension. Moy concluded that there is no contraindication for 
placement of dental implants in patients with cardiac disease or in any patient regardless of their 
medical condition. “Failure trends were similar between healthy and medically compromised 
patients.” The small sample subjects does not allow reliable or substantial conclusions but is in 
favor to the results shown by Moy et al. 2005. 
 
4.2 ARV Medication 
Tables 5 and 6 show ARV medication taken by the subjects in the study. ARV is recommended 
for anyone with HIV. People on ART take a combination of ARV called an HIV regimen every 
day. There is a wide variety of names and brands of antiretroviral drugs in the market. The ARV 
drugs are classified into six drug classes based on how each drug interferes with the HIV life 
cycle. These six classes include the nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand 
transfer inhibitors (ISTIs), entry inhibitors and chemokine co-receptor antagonists (CCR5 
antagonists). The last two ARV mentioned were not included in the clusters because none of the 
subjects used this meds. (Hammett et  al. 1999) 
Table 6 shows the percentages of classes of ARV medication used by the research 
subjects. ARV in this table include all medication taken individually and in combination of a 
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HIV regimen. Most combinations and single doses include one or two types of  NRTI (93.%). 
The other types of ARV are distributed used are ISTI (37.5%), NNRTI (33.%) and PI (32.5%). 
Subjects took a combination of one or two NRTI in combination another with NNRTI (total 
n=23), NRTI with ISTI (n=20) or NRTI with PI (n=17). Wider combinations of ARV were seen 
in this study. These combinations of medication are more recent and therefore common in our 
study. Combinations of NRTI, ISTI and NNRTI n=1, NRTI, PI and ISTI n=6, NRTI, PI and ISTI 
n=6 and the combination of all 4 ARV together was reported in 3 subjects. Oliveira et al. (2011) 
reported in a pilot study the success rate of dental implants in HIV positive subjects taking 
HAART. Unlike this study, Oliveira’s was a prospective study. Fifty-nine implants placed were 
followed for 12 months. The success of the implants was analyzed in relation to CD4
+ 
cell 
counts, viral load and baseline pyridinoline and deoxypyridinoline values. In the introduction of 
the article Oliveira mentions the use of HAART is associated with several adverse effects 
including bone disorders such as osteopenia, osteonecrosis and osteoporosis. Based on this study 
and other limited data published.  
Pan et al. (2006) described the association between osteopenia and osteoporosis with the 
usage of HAART in HIV positive patients. “Several factors have been demonstrated to influence 
HIV-associated decreases in bone mineral density (BMD) including administration of nucleoside 
reverse transcriptase inhibitors (NRTIs).” BMD has been associated with implant failure in the 
general population. In implant dentistry the quality of bone including the BMD can be evaluated 
through the use of Lekholm and Zarb Classification of 1985. Although the classification is based 
only on radiographic evaluation and tactile force during drilling it is possible to correlate bone 
mineral density to the types of bone presented (Chrcanovic, 2017). For example Type IV bone is 
considered to be a cortical layer surrounding a core of low density bone. A recent systematic 
review by Chrcanovic 2017 showed that implants in type IV bone, the least dense bone, tend to 
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have a greater risk of failure than implants placed in type I, II or III bone. Lower BMD has been 
shown to lead to greater risk of failure.  
“The success of osseointegration depends in part on the state of the host bone and its 
healing capacity.” (Chrcanovic, 2014). Pan et al. (2006) mentions that the use of HAART, 
specifically NRTI which is the ART most commonly reported in the study is correlated with 
higher incidences of osteoporosis. Osteoporosis is associated with a decrease in bone mass and 
density therefore a greater risk of lack of osseointegration (Dao, 1993). Studies on this topic are 
scarce and limited. Wagenberg found no significant difference in implant failure rate associated 
with osteoporosis (Wagenberg et al. 2006). All implants placed in the pilot study by Oliveira et 
al. were asymtomatic and  osseointegrated without clinical complications at 12-month follow-up. 
The study concluded that success of dental implants in HIV positive patients is a predictable and 
well-tolerated option regardless their CD4
+ 
cell count, viral load and ART medication taken. 
Longer follow-ups are still required to establish long-term success. Osseointegration in HIV 
positive patients taking HAART or ART are successful. Their short-term success can be seen in 
studies such as Oliveira et al. but the long-term predictability has not yet been determined and 
neither has the effect of ART medication on the relationship of implant placement and longevity. 
Table 8 shows the number of dental implants placed per patient. 142 implants were 
evaluated in total. Most subjects had 1 or 2 implants installed and both groups had 37.3% success 
rate. A single subject had 6 implants. Eighty percent of the subjects were partially edentulous 
and 20% were fully edentulous, see Table 9.  
Table 10 shows the number of patients who presented with clinical signs of periodontal 
disease such as BOP, suppuration, attachment loss greater than 2mm and/or periodontal pocket 
depth greater than 6mm in more than 2 teeth. The Exam group was comprised of a patient 
population that was 60% healthy, 33.3% diagnosed with periodontal disease and 6.7% were 
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completely edentulous. The majority of subjects in this study showed good oral hygiene habits as 
reflected in periodontal health. 
Bone grafts have been related to greater failure rate of dental implants. In this study 
(Table 11) 87.2% of the implants placed had a bone graft placed previously or at implant 
placement. Both guided bone regeneration and previous socket graft to implant placement were 
considered as bone augmentation.  
 
4.3 Implant Parameters 
Tables 12-17 are related to the type of implant placed and not the subject. Table 12, 13 and 14 
related to the prosthetic aspect of the implant. Table 12 shows the percentages of implants 
retention.  46.4% were fixed screw-retained, 45.4% fixed cemented and 8.2% removable screw-
retained locators for overdentures. Table 13 shows that most implants 75% were single unit 
crowns. Table 12 shows most cases occluding against natural teeth (69%) 21% against fixed 
prosthesis on any implant or dental supported fixed porcelain partial denture and 10.1% against a 
removable acrylic partial or complete prosthesis.  
Table 15,16 and 17 shows the implant brand length and diameter. The leading brands of 
implants placed at GSDM were Straumann 43% and Nobel Implants 32.6%. The most common 
implant diameters were 4.7mm and 6.0mm totaling 78%, 3.3mm 17%  and 4.1mm 18% 
respectively. Wider diameter implants are traditionally placed in posterior segments and narrow 
implants are used at sites with limited width as well as in anterior segments. Lastly, implant 
length is shown in Table 17. The most common length is 10mm (65.1%) , 8.0mm (13.18%) 
followed by 11.5mm (10.9%). Other lengths varied between 5.3-1.6%. 
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4.4 Marginal Bone Loss 
Table 18 displays the marginal bone loss also known as crestal bone loss. Bone loss was 
measured on  PA’s radiographs of the implant taken at the day of the research appointment and 
compared to the bone level of the implant the day it was placed in the bone. The criteria used to 
determine the success or failure of dental implants was the Albrektsson’s Criteria for Success 
published in 1986. This is a popular, well-known criteria based on clinical and radiographic 
findings to set parameters for evaluation. Ideally implants are screened annually using this 
criteria to assess their success. Unfortunately these parameters have not been strictly measured in 
the subjects evaluated in this study. Although the ideal guidelines have not been used the 
majority of the subjects follow a strict regimen of maintenance every 3-4 months and have dental 
check-ups at least once a year. These types of patients tend to be conscious of their overall and 
dental health, comply with their prescribed medication and tend to participate in research studies. 
Only a few subjects had not been seen by a dentist for multiple years. None of the implants had 
clinical symptoms of failure such as pain, infection, paresthesia, neuropathies or violation of the 
mandibular canal. All implants were rehabilitated, did not present with mobility or show any 
peri-implant radiolucency. Table 19 shows the duration that each dental implant was present in 
the subjects oral cavity. Irregardless to the loading times or rehabilitation delivery. The average 
length of time in the oral cavity in this study was 43 months (3.6 years). The longest duration of 
an implant was 139 months (11.6 years). In the examination group the longest duration was an 
implant that was placed in August, 2011 for a total of 72 month duration and the bone loss was 
documented at 0.6mm.  The rest of the subject charts review were between 1 month and 15 
years. This large range of time made it an unreliable to draw conclusions. Crestal bone loss for a 
successful implant should be less than 0.2mm annually following the 1st year of service. Several 
implants evaluated in this study had not reached one complete year after loading but were still 
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taken into consideration in the radiographic evaluation. On average mesial bone loss was 0.7mm 
and distal bone loss 0.4mm over 3.6 years. Only one implant in the study did had enough bone 
loss to be considered failing. The single subject had an implant placed in site number 5 and had 
bone loss around the implant in mesial (5.3mm) and distal (6mm). It was more than one-third of 
the length of the implant. The patient complained as well about the esthetics of the crown. This 
implant was the only implant in the study considered failing and the patient will have it removed. 
Clinical examination revealed clear hyper-occlusion on the implant crown. Hyper-occlusion on 
the implant may be the cause for bone loss. This patient maintained good oral hygiene and 
followed a strict protocol of 4 month recall for cleanings annually. Marginal bone loss has been 
demonstrated to be initiated by poor clinical handling (Albrektsson, 2013). Rapid changes in 
loading or reactions to cement particles accidentally embedded in the soft tissue are two reasons 
for marginal bone loss after osseointegration. 
Other than the one failing implant in a single subject, the rest of the implants evaluated 
both clinically and radiographically were successful based on the Albrektsson’s Criteria for 
Success. 
All patients evaluated were satisfied with the treatment. This study supports agrees dental 
implants maintained with good oral hygiene will be successful regardless of the patient medical 
status in this case HIV positive and the usage of ART. 
A systematic review published by Heitz-Mayfield (2008) about diagnosis and risk of 
peri-implant diseases mentions poor oral hygiene as a risk indicator. Very poor oral hygiene is 
associated with peri-implantitis. Heitz-Mayfield also mentioned diabetes and genetic traits as 
systemic unmodifiable factors that increase the risk of peri-implantitis. HIV is considered both 
systematic and non-modifiable, unlike smoking, and it is not mentioned as a risk, nor  is the use 
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of ART. The conclusion of that review support the hypothesis in this study, that systematic 
diseases controlled by medication do not increase the risk of implant failure.  
 
4.5 Conclusion 
The main limitations in this study was primarily the amount of data that could be obtained from 
the subjects and the number of subjects evaluated. Clinical findings such as bleeding upon 
probing (BOP), pocket depth (PD) around the implant or the width of keratinized tissue were not 
considered. The width of keratinized tissue is considered a local factor that may increase the risk 
of peri-implantitis (Heitz-Mayfield, 2008). This parameters was evaluated as the the study 
focused on the bone loss. This information can not easily be retrieved from dental files. To 
obtain substantial results from this study, the minimal number of participating subjects in the 
radiographic analysis should have been 100. The distortion of the radiographs limits the 
precision of bone loss measurements. Ideally before implant placement a custom intraoral PID 
would be fabricated to reproduce the implant alignment to the correct beam angulation and beam 
centering for every follow-ups after placement. Is this study the same positioning of the PID and 
the beam was not able to be accurately positioned to the initial radiography right after implant 
placement. Similar positioning was done but lacked precision. To compensate for radiograph 
angulation distortion, measurements were based on the length and diameter of the implant to 
calibrate the ruler used to measure crestal bone loss. Efforts done to reduce variability and 
inaccuracy provide useful data but not the ideal for radiographic measurements.  
Significant time and resources have been dedicated to find a cure to eradicate HIV 
disease but until this point is reached, therapeutic treatment is the only way to confront it. 
Quality of life, at least in the United States, has improved drastically with the development of 
ART and due in part to the care that is available by the Ryan White Foundation. HIV positive 
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patients do not have the added burden of worrying about the cost of healthcare and particularly 
expensive drug combinations as is ART. This has helped patients be more compliant with drug 
regimens resulting in improved medical status, thus reflected in their oral care. Dental implants 
have proven to be a successful treatment for both the general population and HIV positive 
subjects. To what extend remains questionable. Long-term studies are needed to draw 
conclusions about the success of dental implant in HIV positive patients. It is still unknown if the 
HIV virus may negatively affect osseointegration or whether ART leads to greater extent of 
crystal bone loss than expected from the general population. This study does not answer this 
questions but does support and encourage implant placement in HIV positive subjects as long as 
their health is stable, their HIV is controlled with ART and understand that good oral hygiene 
plays a major role in the success of dental implants.  
Compliant patients as seen in this study follow strict habits of medication protocols and 
optimal hygiene status. By continuing hygiene recalls and proper oral hygiene habits are the 
optimal type of patients for implant placement. 
  
 48 
 
APPENDICES  
APPENDIX A: INITIAL OPT-OUT LETTER FOR PATIENT RECRUITMENT 
 
Dear Mr./ Ms. (last name), 
 
My name is Dr. Gail McCausland, I am the Clinica Director and Clinical Associate Professor for 
the Periodontology Department in Henry M. Goldman School of Dental Medicine (GSDM). I am 
the writing to tell you about a research study we are conducting at the GSDM. The study is 
looking at dental implants and how they perform over time. Dr. Nadine Cordero D.D.S. from our 
research team will be in charge of the data collection. 
 
You have been contacted because you have had dental implants placed within the last 20 years at 
the GSDM. 
 
The study will involve a one-time appointment to the BU School of Dental Medicine.  During 
this visit we will perform an X-ray of your dental implant and a dental exam for research 
purposes. As a gesture of appreciation for the time and effort of participating in the research, a 
complimentary dental examination and dental cleaning will be done, and a gift card for $25 at 
CVS/pharmacy store will be given.  
 
I will contact you shortly via email or telephone to follow up on this letter.  If you are interested 
in participating in the study, I will schedule a 2-hour appointment. 1 hour for assessment and 1 
hour for dental cleaning. 
 
If you do not wish to hear about this research study and do not wish to be contacted again about 
this study, please check box on the enclosed form and return it to the researcher in the pre-paid 
envelope.  
 
If we do not receive your reply within a month, a research team member may send you another 
letter and/or contact you by phone.   
 
Thank you for your consideration. 
 
Sincerely, 
 
 
Gail McCausland, DMD 
Clinical Associate Professor 
Boston University Henry M. Goldman School of Dental Medicine 
Periodontology Department 
100 E. Newton St Goldman SDM 
Boston MA 02118 
Phone (617) 638-4862 
gaillmc@bu.edu 
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Nadine Cordero Rubinstein DDS 
Periodontal Resident  
Boston University Henry M. Goldman School of Dental Medicine 
 
Dear Dr. Gail McCausland, 
 
I understand you will be conducting a research in Henry M. Goldman School of Dental Medicine 
to acquire further knowledge of dental implants to the scientific field.  
 
I do not wish to participate in the research. Please do not contact me anymore. 
 
Sincerely, 
 
 
_________________________________ 
Name in print letters 
 
_________________________________ 
Signature 
 
_________________________________ 
Date 
  
 50 
 
APPENDIX B: SECOND ATTEMPT PHONE CALL SCRIPTS FOR PATIENT 
RECRUITMENT 
 
Good morning/afternoon.  I’m calling from Boston University School of Dental Medicine.  May 
I speak with xxxxxxxxx? 
 
[If the potential subject is available, continue.  If not available determine best time to call back 
and/or leave return number or e-mail address] 
 
My name is Dr. Nadine Cordero. I am a periodontal resident at the Boston University Henry M. 
Goldman School of Dental Medicine.  
 
I would like to tell you about a research study I am conducting with Dr. Gail McCausland who is 
a Clinical Associate Professor here at the GSDM.  Dr. McCausland is the Clinic Director of the 
Department of Periodontology. 
 
Our research is focused on dental implants placed at the GSDM within the last 20 years. I am 
calling you today because you have had an implant placed at GSDM years ago and might be 
interested in participating. 
 
The study involves a one-time appointment to the BU School of Dental Medicine.  During this 
visit we will take an X-ray of your dental implant and perform a dental exam for research 
purposes. For your time and effort of participating in the research, a complimentary dental 
examination and dental cleaning will be offered, and a $25 value gift card for CVS/pharmacy 
will be given. 
 
 
Would you be interested in participating?  If so, we can schedule an appointment for your 
research visit.  At that time we will review the research consent form.  Would you like to 
schedule the appointment today?  
 
 
Subject: Yes. 
 
[Continue with scheduling the appointment, updating contact information, and providing 
directions for getting to the visit, etc.] 
 
 
Subject: No. 
 
Thank you very much for your time. We will not contact you again regarding this research. 
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APPENDIX C: PATIENT-RELATED QUESTIONNAIRE 
 
ID _________________   DATE: _______/________/___________ 
 
Patient-Related Questionnaire 
1. Age  ____________ 
2. Gender:  Male(1) Female(2) 
3. Date diagnosed with HIV+? month/day/year  _______/_______/________ 
4. CD4 Count (number of cells in cubic millimeter of blood)(Specific Number)  
___________ 
5. Are you taking any antiretroviral therapy? Yes (1) No(0) 
6. Antiretroviral therapy taken: 
 Retrovir (zidovudine, azidothymidine, AZT, ZDV) (1) 
Trizivir (abacavir, zidovudine, and lamivudine) (2) 
Truvada (tenofovir disoproxil fumarate and emtricitabine) (3) 
Videx (enteric coated didanosine, ddI EC) (4) 
Other (specify): 
______________________________________________________________ 
7. Other medications you are currently taking.  List: 
 ______________________________________________________________ 
 ______________________________________________________________ 
 ______________________________________________________________ 
 ______________________________________________________________ 
 ______________________________________________________________ 
 ______________________________________________________________ 
 
8. In your lifetime, did you ever smoke more than 100 cigarettes?       Yes(1) 
No(0) 
9. Do you currently smoke?      Yes (1) 
No(0) 
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10.  Do you have diabetes?      Yes (1) 
No(0) 
11. Have you had a myocardial infarction (heart attack)?   Yes (1) 
No(0) 
       12.   Have you had a stroke?      Yes (1)  No(0) 
13.  Have you been diagnosed with periodontitis (gum disease) before? Yes(1) 
No(0)  
14. In which department was/were the dental implant(s) placed? 
 Periodontal Department (1)  
 Oral Surgery(2) 
 Other specify: ____________________________________  
15. Prosthetic therapy Which department restored the dental implant(s)? 
 Prosthodontic department(0)  
 AEGD(1) 
 External clinic(2)  
Other specifiy: __________________________________  
16. How often do you visit a dental clinic for maintenance and follow-up? 
______________________________________________________________ 
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APPENDIX D: CLINICAL AND RADIOGRAPHIC EXAMINATION 
 
ID _________________   DATE: _______/________/___________ 
 
Clinical and Radiographic Examination 
1. Clinical Findings Edentulous(1) Partially edentulous(2) 
2. Periodontitis current status more than 2 teeth with BOP, suppuration, attachment loss 
greater than 2mm and/or periodontal pocket depth greater than 6mm 
 Healthy(1) 
 Periodontitis(2) 
 Edentulous(3) 
3. Date of implant placement surgery (month/day/year) ________________________ 
4. Implant placed in  Maxilla(1) Mandible(2) 
5. Position  Anterior (canine to canine) (1) Posterior(2) 
6. Was bone augmentation necessary?  
                 Yes(1) No(1)   Missing data(6) 
7. What type of retention was used for the rehabilitation? 
   Screw retained(1) Cemented(2)  Removable(3) 
8. Design of rehabilitation  Single unit(1) Multi-unit(2)   
9. Implant specifications: 
 Length _______________ 
 Diameter _______________ 
 Brand _____________________________________________________________ 
10. Antagonist (implant occludes against)? 
 Natural teeth(1) Fixed prosthesis(2)  Removable prosthesis(3) 
11. Implant mobility measured with Periotest (Specific Number)  __________________ 
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Radiographic examination 
12. Baseline radiography date  (month/day/year) ________________________ 
13. Current recall radiography date (month/day/year) ________________________ 
14. Mesial bone loss in mm  (specific number) ________________________ 
15. Mesial bone loss in percentage (specific number) ________________________ 
16. Distal bone loss in mm  (specific number) ________________________ 
17. Distal bone loss in percentage(specific number) ________________________ 
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APPENDIX E: DENTAL IMPLANT  INFORMATION FOR RADIOGRAPHIC 
ANALYSIS 
Table 20. Dental Implant  Information for Radiographic Analysis 
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APPENDIX F: CALIBRATION GUIDELINES FOR BONE LOSS MEASUREMENT 
 
Table 21. Calibration Guidelines for Bone Loss Measurement 
Example of bone loss calibration and measurements to determine bone loss.  
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